HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Retrosternal lymphotropic chemotherapy and pneumoperitoneum in the treatment of drug-resistant destructive pulmonary tuberculosis].

Abstract
The efficiency of combined treatment with retrosternal lymphotropic administration of drugs and pneumoperitoneum was comparatively analyzed in 148 new cases of destructive pulmonary tuberculosis. Both methods were applied during combined chemotherapy in a study group of 48 patients. In Group 2 (n = 54), lymphotropic procedure was employed alone during standard chemotherapy; in Group 3 (n = 46), only pneumoperitoneum was used in combination of chemotherapy. In 40 patients, pulmonary tuberculosis was acutely progressive. Drug resistance was identified in 81.7%, including multidrug resistance in 27.7%. With the combined use of retrosternal lymphotropic therapy and pneumoperitoneum, bacterial excretion ceased in 96.2% of new cases of drug-resistant tuberculosis; decay cavity resolved in 80.8%. The proposed therapeutic technology used in patients with persistent bacterial excretion and decay cavities after ineffective 4-9-month treatment could achieve abacillation in 90.9% of patients and resolve decay cavities in 77.3%. Retrosternal drug injection reduces a risk for complications due to bronchial tuberculosis involvement when pneumoperitoneum is applied.
AuthorsB S Kibrik, A V Zakharov, V M LobanovskiÄ­
JournalProblemy tuberkuleza i boleznei legkikh (Probl Tuberk Bolezn Legk) Issue 5 Pg. 21-6 ( 2009) ISSN: 1728-2993 [Print] Russia (Federation)
PMID19565808 (Publication Type: Comparative Study, English Abstract, Journal Article)
Chemical References
  • Antitubercular Agents
Topics
  • Adult
  • Antitubercular Agents (administration & dosage)
  • Female
  • Follow-Up Studies
  • Humans
  • Injections
  • Lymphoid Tissue
  • Male
  • Middle Aged
  • Mycobacterium tuberculosis (drug effects, isolation & purification)
  • Pneumoperitoneum, Artificial (methods)
  • Radiography, Thoracic
  • Sternum
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant (diagnosis, therapy)
  • Tuberculosis, Pulmonary (diagnosis, therapy)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: